Claims

1. A therapeutic agent for ageing macular degeneration, which comprises as an effective ingredient a progesterone derivative represented by the following formula (1):

(wherein, R^1 represents an alkyl group having from 1 to 23 carbon atoms).

- 2. A therapeutic agent for ageing macular degeneration according to Claim 1, wherein the progesterone derivative is 9α -fluoromedroxyprogesterone acetate.
 - 3. A therapeutic agent for ageing macular degeneration according to Claim 1 or 2, wherein the ageing macular degeneration is provided as an eye drop, injection solution to Tenon's capsule, injection solution to ocular fundus, or ointment.
 - 4. Use of a progesterone derivative represented by the following formula (1):

(wherein, R^1 represents an alkyl group having from 1 to 23 carbon atoms) for the preparation of a therapeutic agent for ageing macular degeneration.

- 5. Use according to Claim 4, wherein the progesterone derivative is $9\alpha\text{-fluoromedroxyprogesterone}$ acetate.
- 6. Use according to Claim 4 or 5, wherein the ageing macular degeneration is provided as an eye drop, injection solution to Tenon's capsule, injection solution to ocular fundus, or ointment.
- 7. A treating method of ageing macular degeneration, which comprises administering an effective amount of progesterone derivative represented by the above-described formula (1):

(wherein, R^1 represents an alkyl group having from 1 to 23 carbon atoms).

- 8. A treating method according to Claim 7, wherein the progesterone derivative is $9\alpha-$ fluoromedroxyprogesterone acetate.
- 9. A treating method according to Claim 7 or 8, wherein administration is done in the form of an eye drop, injection solution to Tenon's capsule, injection solution to ocular fundus, or ointment.